Evidence map›Paper›PMID 29939367›Full record

Trial reportSchizophrenia bulletin2018

Efficacy of PRIME, a Mobile App Intervention Designed to Improve Motivation in Young People With Schizophrenia.

Danielle A Schlosser, Timothy R Campellone, Brandy Truong, Kevin Etter, Silvia Vergani, Kiya Komaiko, Sophia Vinogradov

Open access · bronzeAbstract readRandomized Controlled Trial
PubMed Full text at PMC Publisher
In one paragraph

Trial report in Schizophrenia bulletin, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 110 papers, 17 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
110citing papers in PubMed, 17 pooled it
15.9field-weighted citation impact, top 1% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

110 citing papers in PubMed, 17 syntheses or guidelines pooled it, 217 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Mend the Gap: Online User-Led Adjuvant Treatment for Psychosis: A Systematic Review on Recent Findings.International journal of environmental research and public health · 2025
    Pooled it
  4. Pooled it
  5. Pooled it
  6. Pooled it
  7. Pooled it
  8. Pooled it
  9. Pooled it
  10. Pooled it
  11. Pooled it
  12. Pooled it
  13. Pooled it
  14. Pooled it
  15. Pooled it
  16. Pooled it
  17. Pooled it
  18. Trial
  19. Trial
  20. Trial

50 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 3 institutions in 1 country.

Danielle A SchlosserUCSF Weill Institute for Neurosciences, University of California, San Francisco, San Francisco, CA.
Timothy R CampelloneUCSF Weill Institute for Neurosciences, University of California, San Francisco, San Francisco, CA.
Brandy TruongUCSF Weill Institute for Neurosciences, University of California, San Francisco, San Francisco, CA.
Kevin EtterUCSF Weill Institute for Neurosciences, University of California, San Francisco, San Francisco, CA.
Silvia VerganiHealth and Wellness, IDEO, Palo Alto, CA.
Kiya KomaikoUCSF Weill Institute for Neurosciences, University of California, San Francisco, San Francisco, CA.
Sophia VinogradovUCSF Weill Institute for Neurosciences, University of California, San Francisco, San Francisco, CA.
University of California, San Francisco · USIDEO (United States) · USSan Francisco VA Medical Center · US

Funding

Enhancing Functional Outcomes in Schizophrenia Using a Novel mHealth ApproachR34MH100399 · NIMH · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI ANGUERA, JOAQUIN A, VINOGRADOV, SOPHIA · 2013 to 2015
$710k
NIMH NIH HHS R34 MH100399
6 · The paper itself

Abstract

The onset of schizophrenia occurs during a period critical for development of social relationships and functional independence. As such, interventions that target the early course of illness have the potential to stave off functional decline and restore functioning to pre-illness levels. In this entirely remote study, people with recent-onset schizophrenia spectrum disorders (SSDs) participated in a 12-week randomized controlled trial to determine the efficacy of PRIME (personalized real-time intervention for motivational enhancement), a mobile-based digital health intervention designed to improve motivation and quality of life. Participants were randomized into the PRIME (n = 22) or treatment-as-usual/waitlist (TAU/WL) condition (n = 21) and completed assessments at baseline, post-trial (12 wk), and for people in the PRIME condition, 3 months after the end of the trial. After 12-weeks, WL participants received PRIME, resulting in a total sample of 38 participants completing PRIME. In PRIME, participants worked towards self-identified goals with the support of a virtual community of age-matched peers with schizophrenia-spectrum disorders as well as motivation coaches. Compared to the WL condition, people in the PRIME condition had significantly greater improvements in self-reported depression, defeatist beliefs, self-efficacy, and a trend towards motivation/pleasure negative symptoms post-trial, and these improvements were maintained 3 months after the end of trial. We also found that people in the PRIME condition had significantly greater improvements in components of social motivation post-trial (anticipated pleasure and effort expenditure). Our results suggest that PRIME has the potential to be an effective mobile-based intervention for improving aspects of mood and motivation in young people with SSDs.

Indexed as

Mobile ApplicationsMotivationOutcome Assessment, Health CareQuality of LifeSchizophrenic PsychologyAdultFemaleHumansMalePsychotherapySchizophreniaTelemedicineYoung Adult

Identifiers

PMID29939367
PMCPMC6101497
OpenAlexW2808783108

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.